Oramed Pharmaceuticals Inc.

Phase 3 Oral Insulin (ORMD-0801) Trials for the Treatment of Type 2 Diabetes: Over 75% Enrollment Completed 

Upcoming Milestones:  

6-month topline efficacy results from larger ORA-D-013-1 trial expected in 2022 

ORA-D-013-2 trial expected to complete enrollment in 2022

Oravax Medical, Inc.: Oral COVID-19 Vaccine 

Upcoming Milestones:  

Topline data from Phase 1 expected H1 2022 

Initiation of Phase 2/3 oral COVID-19 vaccine trials expected H2 2022 

Phase 2 NASH Trial: 50% Enrollment Completed

Upcoming Milestones:  

Enrollment completion expected H1 2022 

Topline data expected in H2 2022

Oral GLP-1 

Upcoming Milestone:  

Bioavailability (PK and PD) expected in H1 2022 

https://www.oramed.com/oramed-issues-annual-message-to-shareholders/

Oramed’s Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

– 76 Percent of the Physicians Responded They “Definitely Would” or “Probably Would” Prescribe Oramed’s Oral Insulin Candidate for Type 2 Diabetes Patients

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians - Oramed Pharmaceuticals